Two brands enjoy big market share boosts as market barriers hinder competitors
Market barriers affect more than a third of asthma/COPD prescriptions in the US. According to our survey, roughly 55% of doctors can't prescribe certain brands because they're either too expensive, or not available of formularies. Not all brands lose out, though. Two of the leading treatments get a market share bump of almost 5% because doctors can't prescribe competitors.
Market Access Impact: Asthma/COPD (US) shows you how 7 barriers affect your market share, revealing how much you win and lose, who you take share from, and who gets your lost share.
Based on a survey of 100 US-based pulmonologists and primary care physicians, the report covers 12 major therapies from AstraZeneca, Boehringer Ingelheim, GSK, Novartis , and Roche .
- Barriers affect more than a third of prescriptions: The two biggest barriers have a bigger impact than all other barriers combined.
- Two brands see impressive market share gains: Each sees a net increase of nearly 5% because barriers prevent doctors from prescribing competing treatments.
- Most brands lose: 8 of the 12 surveyed brands see a net market share loss, although many of those losses are modest.
- Few brands are widely prescribed: Only 4 brands are prescribed by more than about 65% of doctors. However, many doctors are willing to consider brands they don't prescribe.
- More doctors experience cost and formulary availability barriers: Roughly 20-40% of doctors can't prescribe most brands because they're too expensive or not available on formularies.
- Low awareness is a problem for some brands: 20-30% of doctors simply haven't heard of 4 of the surveyed brands.
Insight into 12 Major Asthma/COPD Drugs
- Symbicort (budesonide/formoterol; AstraZeneca)
- Advair (fluticasone/salmetrol; GSK)
- Spiriva (tiotropium; Boehringer Ingelheim)
- Tudorza (aclidinium; AstraZeneca)
- Anoro (umeclidinium/vilanterol; GSK)
- Arcapta (indacaterol; Novartis)
- Utibron (indacaterol/glycopyrronium; Novartis)
- Seebri (glycopyrronium; Novartis)
- Daliresp (roflumilast; AstraZeneca)
- Nucala (mepolizumab; GSK)
- Xolair (omalizumab; Novartis/Roche)
- Breo Ellipta (vilanterol/fluticasone furoate; GSK)
Exploring Market Access Barriers
Market Access Impact:Asthma/COPD (US) explores key issues affecting drug manufacturers. You'll learn:
How barriers affect market access:
- What brands do doctors prescribe the most?
- How many prescriptions do barriers affect?
- Which barriers have the biggest impact?
How barriers affect your brand:
- How many doctors prescribe your brand? How many don't, but would consider it?
- Why don't doctors prescribe your brand? What do they prescribe instead?
- Which competing brands does your brand take market share from?
A Report Based on Expert Knowledge
We surveyed 100 US-based pulmonologists and primary care physicians, chosen from the largest community of validated physicians in the world.
All respondents have:
- Been practicing for 2+ years
- Prescribed at least one of the listed products
- Seen at least 5 patients with asthma and/or COPD in total in the last month
We conducted the survey between between June 1st and 5th, 2017.